The influence of creatine on brain functioning
DOI:
https://doi.org/10.12775/QS.2026.61.72930Keywords
creatine, brain function, cognition, memory, processing speed, neurodegenerative diseases, depression, mood dissorders, mitochondrial function, ATP metabolism, neuroprocetion, supplementationAbstract
Creatine is a key component of cellular energy metabolism, supporting ATP resynthesis. Increasing attention has been given to its potential effects on brain function, including cognition, mood regulation, and neuroprotection. The aim of this review was to summarize current evidence on the effects of creatine supplementation on brain function, with a focus on cognitive performance, neurodegenerative diseases, and affective disorders. The literature review included randomized controlled trials, clinical and observational studies, as well as experimental research identified in major scientific databases. Creatine acts primarily by enhancing cellular bioenergetics, increasing ATP availability, and supporting mitochondrial function. The evidence suggests modest cognitive benefits, particularly improvements in memory and processing speed, especially under conditions of increased metabolic demand, such as sleep deprivation or cognitive fatigue. In neurodegenerative diseases, findings remain inconsistent—despite promising preclinical data, large clinical trials have not demonstrated significant therapeutic effects. In affective disorders, particularly depression, creatine shows potential as an adjunctive treatment, enhancing the effectiveness of standard therapies. However, in bipolar disorder, supplementation may carry a risk of triggering manic or hypomanic episodes. Overall, creatine supplementation is a biologically plausible, generally safe, and well-tolerated intervention with context-dependent effects on brain function. While it may provide modest cognitive benefits and support the treatment of depression, current evidence does not justify its use as a primary therapy for neurodegenerative diseases. Further large-scale, well-designed studies are needed to clarify its clinical utility in neuropsychiatric conditions.
References
1. Forbes SC, Cordingley DM, Cornish SM, Gualano B, Roschel H, Ostojic SM, et al.
Effects of Creatine Supplementation on Brain Function and Health. Nutrients. 22 lutego
2022;14(5):921. doi:10.3390/nu14050921 PubMed PMID: 35267907; PubMed Central
PMCID: PMC8912287.
2. Swatko T, Blicharz M, Czubala M, Bartosik-Zielińska D, Blicharz A, Bartosik M. Effects
of creatine supplementation on brain in the healthy population. J Educ Health Sport. 2
maja 2023;13(4):160–5. doi:10.12775/JEHS.2023.13.04.017
3. Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for
cerebral functions. J Neurochem. 2010;115(2):297–313. doi:10.1111/j.1471-
4159.2010.06935.x
4. Institute of Medicine (US) Committee on Nutrition T, Erdman J, Oria M, Pillsbury L.
Creatine. W: Nutrition and Traumatic Brain Injury: Improving Acute and Subacute Health
Outcomes in Military Personnel [Internet]. National Academies Press (US); 2011
[cytowane 17 kwietnia 2026]. Dostępne na:
https://www.ncbi.nlm.nih.gov/books/NBK209321/
5. Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, et al.
International Society of Sports Nutrition position stand: safety and efficacy of creatine
supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 13 czerwca
2017;14(1):18. doi:10.1186/s12970-017-0173-z
6. Wallimann T, Tokarska-Schlattner M, Schlattner U. The creatine kinase system and
pleiotropic effects of creatine. Amino Acids. 1 maja 2011;40(5):1271–96.
doi:10.1007/s00726-011-0877-3
7. Kreider RB, Gonzalez DE, Hines K, Gil A, Bonilla DA. Safety of creatine
supplementation: analysis of the prevalence of reported side effects in clinical trials and
adverse event reports. J Int Soc Sports Nutr. 22(Suppl 1):2488937.
doi:10.1080/15502783.2025.2488937 PubMed PMID: 40198156; PubMed Central
PMCID: PMC11983583.
8. Gonzalez DE, Dickerson BL, Hines K, Chun J, Gil A, Forbes SC, et al. Creatine
Supplementation Dose and Duration Are Not Associated with Increased Side Effects: A
Structured Review and Study-Level Dose–Response Analysis of Randomized Controlled
Trials. Sports. kwietnia 2026;14(4):137. doi:10.3390/sports14040137
9. Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, et al. Prophylactic
Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice. J
Neurosci. 30 czerwca 2004;24(26):5909–12. doi:10.1523/JNEUROSCI.1278-04.2004
PubMed PMID: 15229238; PubMed Central PMCID: PMC6729248.
10. Mallik B, Frank CA. Is creatine a CNS neurotransmitter? eLife. 12:e91824.
doi:10.7554/eLife.91824 PubMed PMID: 37843902; PubMed Central PMCID:
PMC10578925.
11. Meftahi GH, Hatef B, Pirzad Jahromi G. Creatine Activity as a Neuromodulator in the
Central Nervous System. Arch Razi Inst. 31 sierpnia 2023;78(4):1169–75.
doi:10.32592/ARI.2023.78.4.1169 PubMed PMID: 38226371; PubMed Central PMCID:
PMC10787915.
12. Bender* A, Auer* DP, Merl T, Reilmann R, Saemann P, Yassouridis A, et al. Creatine
supplementation lowers brain glutamate levels in Huntington’s disease. J Neurol. 1
stycznia 2005;252(1):36–41. doi:10.1007/s00415-005-0595-4
13. Xu C, Bi S, Zhang W, Luo L. The effects of creatine supplementation on cognitive
function in adults: a systematic review and meta-analysis. Front Nutr. 12 lipca 2024;11.
doi:10.3389/fnut.2024.1424972
14. Gordji-Nejad A, Matusch A, Kleedörfer S, Jayeshkumar Patel H, Drzezga A, Elmenhorst
D, et al. Single dose creatine improves cognitive performance and induces changes in
cerebral high energy phosphates during sleep deprivation. Sci Rep. 28 lutego
2024;14(1):4937. doi:10.1038/s41598-024-54249-9
15. Smith AN, Morris JK, Carbuhn AF, Herda TJ, Keller JE, Sullivan DK, et al. Creatine as a
Therapeutic Target in Alzheimer’s Disease. Curr Dev Nutr. 29 września
2023;7(11):102011. doi:10.1016/j.cdnut.2023.102011 PubMed PMID: 37881206;
PubMed Central PMCID: PMC10594571.
16. (PDF) Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and
cognition. ResearchGate. 11 marca 2026. doi:10.1002/trc2.70101
17. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 29 sierpnia 2015;386(9996):896–912.
doi:10.1016/S0140-6736(14)61393-3 PubMed PMID: 25904081.
18. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson
disease. Nat Rev Dis Primer. 23 marca 2017;3:17013. doi:10.1038/nrdp.2017.13 PubMed
PMID: 28332488.
19. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD)
Investigators. Effect of Creatine Monohydrate on Clinical Progression in Patients With
Parkinson Disease: A Randomized Clinical Trial. JAMA. 10 lutego 2015;313(6):584–93.
doi:10.1001/jama.2015.120
20. Mo JJ, Liu LY, Peng WB, Rao J, Liu Z, Cui LL. The effectiveness of creatine treatment
for Parkinson’s disease: an updated meta-analysis of randomized controlled trials. BMC
Neurol. 2 czerwca 2017;17(1):105. doi:10.1186/s12883-017-0885-3
21. Jurcau A. Molecular Pathophysiological Mechanisms in Huntington’s Disease.
Biomedicines. czerwca 2022;10(6):1432. doi:10.3390/biomedicines10061432
22. Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, et al. The CREST-
E study of creatine for Huntington disease. Neurology. 8 sierpnia 2017;89(6):594–601.
doi:10.1212/WNL.0000000000004209 PubMed PMID: 28701493; PubMed Central
PMCID: PMC5562960.
23. Poletti S, Mazza MG, Benedetti F. Inflammatory mediators in major depression and
bipolar disorder. Transl Psychiatry. 8 czerwca 2024;14(1):247. doi:10.1038/s41398-024-
02921-z
24. Chand SP, Arif H. Depression. W: StatPearls [Internet] [Internet]. StatPearls Publishing;
2023 [cytowane 1 maja 2026]. Dostępne na:
https://www.ncbi.nlm.nih.gov/books/NBK430847/ PubMed PMID: 28613597.
25. Sherpa NN, De Giorgi R, Ostinelli EG, Choudhury A, Dolma T, Dorjee S. Efficacy and
safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in
depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and
exploratory trial in an under-resourced area. Eur Neuropsychopharmacol. 1 stycznia
2025;90:28–35. doi:10.1016/j.euroneuro.2024.10.004
26. A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate
Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in
Women With Major Depressive Disorder. Am J Psychiatry [Internet]. [cytowane 1 maja
2026]. Dostępne na: https://psychiatryonline.org/doi/10.1176/appi.ajp.2012.12010009
27. Charney AW, Mullins N, Park YJ, Xu J. On the diagnostic and neurobiological origins of
bipolar disorder. Transl Psychiatry. 23 kwietnia 2020;10(1):118. doi:10.1038/s41398-020-
0796-8
28. Toniolo RA, Silva M, Fernandes F de BF, Amaral JA de MS, Dias R da S, Lafer B. A
randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine
monohydrate as adjunctive treatment for bipolar depression. J Neural Transm. 1 lutego
2018;125(2):247–57. doi:10.1007/s00702-017-1817-5
29. Ovid [Internet]. [cytowane 1 maja 2026]. Creatine monohydrate in resistant depression :
Bipolar Disorders. Dostępne na: https://www.ovid.com/journals/bipdi/fulltext/00129219-
200711000-00011~creatine-monohydrate-in-resistant-depression-a-preliminary
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dominika Lewandowska, Katarzyna Otrębska, Aleksandra Makulec, Natalia Kostecka, Aleksandra Jóźwik-Szymańska, Laura Mikuła, Aleksandra Szredzka, Zuzanna Bogdan-Groszyk, Jan Kucharski

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 187
Number of citations: 0